Tuberculosis vaccine development in the Mouse model
  • Bo-Young Jeon
  • SLS Colloquia / Oct 27th 04:00 pm / Engineering Building 1st E104

Tuberculosis (TB) is a major infectious disease and has threatened human health; causing more than 3 million deaths each year and about one-third of the world’s population are latently infected with Mycobacterium tuberculosis.

The situation has been worsened by emergence of multi-drug or extensively drug resistant Mycobacterium tuberculosis and combination with HIV infection. CD4+ T cells are involved in protection against M. tuberculosis. M. tuberculosis-specific-CD4+ Th1 cell response is considered to have a protective role for the ability to produce cytokines such as IFN-g or TNF-a that contribute to the recruitment and activation of innate immune cells, like monocytes and granulocytes.

The BCG vaccine against TB has been widlely used, but its efficacy remains controversial. More effective novel vaccine candidates have been developed to protect against pulmonary TB either in TB naive or in latent TB. Subunit vaccine composing TB-protein antigens in adjuvants, recombinant BCG vaccine expressing TB specific antigens, and DNA vaccines having TB antigen genes in plasmid DNA have been applied and evaluated as a prophylactic vaccine or therapeutic vaccines using an aerosol challenge mouse model.